D-penicillamine, a non-bilirubin-displacing drug in neonatal jaundice.
D-penicillamine, a drug used clinically for the treatment of neonatal hyperbilirubinaemia, was tested for interference with the binding of bilirubin to human serum albumin by three methods: 1) The peroxidase technique, investigating the effect of D-penicillamine on the equilibrium concentration of unbound bilirubin in a solution containing a molar excess of albumin; 2) the MADDS method, measuring the concentration of vacant bilirubin binding site on albumin in a solution of pure albumin, or infant blood serum, with added D-penicillamine; and 3) injection of D-penicillamine into Gunn rats and determination of any decrease of plasma bilirubin which would be caused by displacement of the pigment. Results were negative in all cases. Quantitatively, the doses of D-penicillamine used clinically cannot displace bilirubin from its binding to albumin. The ameliorating effect on hyperbilirubinaemia in the newborn must be due to some other mechanism.
D000818:Animals; D001663:Bilirubin / Q000378:metabolism*; D001667:Binding, Competitive; D003622:Dapsone / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000188:drug therapy*; D010396:Penicillamine / Q000032:analysis / Q000627:therapeutic use*; D011485:Protein Binding; D051381:Rats; D012709:Serum Albumin / Q000378:metabolism
D012709:Serum Albumin; D003622:Dapsone; C018965:monoacetyldapsone; D010396:Penicillamine; D001663:Bilirubin